Cargando…
Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer
This article comments on the approaches to solving problems in the development of targeted drug therapies for cancer as outlined by expert collaborative panels and described in this issue by Amit et al., Abrams et al., and Clark et al.
Autores principales: | Schilsky, Richard L., Allen, Jeff, Benner, Joshua, Sigal, Ellen, McClellan, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227984/ https://www.ncbi.nlm.nih.gov/pubmed/20489184 http://dx.doi.org/10.1634/theoncologist.2010-0079 |
Ejemplares similares
-
Data Submission Standards and Evidence Requirements
por: Abrams, Jeffrey, et al.
Publicado: (2010) -
RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
por: Strand, Vibeke
Publicado: (2021) -
5-hydroxymethylcytosine marks regions with reduced mutation frequency in human DNA
por: Tomkova, Marketa, et al.
Publicado: (2016) -
Effects of a Clinical Exercise Program on Health-Related Fitness and
Quality of Life in Spanish Cancer Patients Receiving Adjuvant
Therapy
por: GilHerrero, Lucía, et al.
Publicado: (2022) -
Tumor Targeting by Conditioned Medium Derived From Human Amniotic Membrane: New Insight in Breast Cancer Therapy
por: Jafari, Ameneh, et al.
Publicado: (2021)